12月22日，国际著名杂志Nature刊登了国外研究人员的最新研究成果“Cancer immunotherapy comes of age。”文章中，研究者揭示了用于癌症治疗的主动免疫疗法的最新进展。
利用单克隆抗体和供体T细胞进行的被动免疫疗法对某些类型的癌症是有效的，但尽管人们进行了广泛研究，对特定的、有耐久性的抗肿瘤免疫实施主动刺激仍然难以实现。最近，随着用于前列腺癌的sipuleucel-T疗法和用于一些转移性黑素瘤的ipilimumab药物的研发成功，这种情况已经得到改变。这些成果使人们对癌症免疫疗法重新产生了兴趣。这篇Review文章总结了有关疫苗、T细胞免疫调控因子和其他活性免疫刺激药物的最新研究工作，这些药物与定向疗法相结合，可能会导致未来癌症治疗方法的问世。（生物谷Bioon.com）
doi:10.1038/nature10673
PMC:
PMID:
Cancer immunotherapy comes of age
Ira Mellman,George Coukos& Glenn Dranoff
Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.
